Single Patient Safety Concern Hits Allogene’s Off-The-Shelf CAR-T
All Of Company’s Trials Halted
Allogene is the frontrunner in the allogeneic CAR-T field but must assess whether or not its therapy could have caused a patient’s unexpected chromosomal abnormality.
